WARRINGTON, Pa., March 20, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company focused on developing its proprietary surfactant replacement therapies to address various respiratory conditions, announced today that the United States District Court for the Eastern District of Pennsylvania, granted the Company’s Motion to Dismiss the Second Consolidated Amended Complaint that was filed against the Company and two of its executive officers on November 30, 2006.
